Baseline characteristics

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet · Source last updated 2025-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      52

   units

   Participants

groups

1. description

   Carfilzomib was administered intravenously on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression or end of study. A dose of 20 mg/m\^2 was administered on day 1 of cycle 1; all subsequent doses were 56 mg/m\^2. From cycle 13, the frequency of carfilzomib administration was reduced to days 1 and 15 (± 2 days) per cycle until progression or end of study. Dexamethasone was administered orally or intravenously at a dose of 40 mg on days 1, 8, 15, and 22 of each cycle during cycles 1 to 12, and at a dose of 20 mg on days 1 and 15 from cycle 13 until progression or end of study. Pomalidomide 4 mg was administered orally on days 1 to 21 of each cycle until progression or end of study.

   id

   BG000

   title

   Carfilzomib With Pomalidomide and Dexamethasone (KPd)

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            9.4

            value

            66.2

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            28

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            24

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            4

         title

         Hispanic or Latino

      2. measurements

         1. group Id

            BG000

            value

            45

         title

         Not Hispanic or Latino

      3. measurements

         1. group Id

            BG000

            value

            3

         title

         Unknown or Not Reported

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Ethnicity (NIH/OMB)

   unit Of Measure

   Participants

4. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            1

         title

         Asian

      2. measurements

         1. group Id

            BG000

            value

            1

         title

         Black or African American

      3. measurements

         1. group Id

            BG000

            value

            47

         title

         White

      4. measurements

         1. group Id

            BG000

            value

            3

         title

         Other

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Race/Ethnicity, Customized

   unit Of Measure

   Participants

population Description

Baseline measures are presented for the safety analysis set which included participants who received at least 1 dose of carfilzomib.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice